Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Direct Oral Anticoagulants Doacs

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03596502Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)

NCT03568916Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Showing all 2 trials

Research Network

Common Treatments

  • Direct Oral Anticoagulants Doacs1
  • Apixaban Atc B01af021
  • Dabigatran Atc B01ae071
  • Rivaroxaban Atc B01af011
  • Warfarin1

Active Sponsors

  • Canadian Network for Observational Drug Effect Studies, CNODES2
  • Canadian Institutes of Health Research (CIHR)2
  • Drug Safety and Effectiveness Network, Canada2

Top Investigators

Related Conditions

  • Myocardial Infarction2
  • Atrial Fibrillation2
  • Allcause Mortality2
  • Major Bleed2
  • Ischemic Stroke2

Activity Timeline